Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of antibacterial peptide YD in preparing drug for treating hepatic fibrosis

A technology of liver fibrosis and antimicrobial peptides, applied in the field of biomedicine, can solve the problems of no reports of antimicrobial peptides

Inactive Publication Date: 2019-08-16
LANZHOU UNIVERSITY
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the role of antimicrobial peptide YD in the treatment of liver fibrosis has not been reported so far.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of antibacterial peptide YD in preparing drug for treating hepatic fibrosis
  • Application of antibacterial peptide YD in preparing drug for treating hepatic fibrosis
  • Application of antibacterial peptide YD in preparing drug for treating hepatic fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0105] Preparation of antimicrobial peptide YD freeze-dried powder for intramuscular injection

[0106] Formula: antibacterial peptide YD (purity greater than 95%) 30.0g

[0107] Specific protein stabilizer, lyoprotectant / excipient 30.0g

[0108] Osmolality regulator (plasma 313 mOsm / kgH 2 O) 0.5-1L

[0109] pH regulator (pH 4-9) 0.5-1L

[0110] Pharmaceutical water Add to total volume 60L

[0111] The total mass of freeze-dried powder is 60.0-70.0g

[0112] Process: According to the conventional process for preparing freeze-dried powder, a total of 1,000 freeze-dried powders were prepared, each containing 60-70 mg of antimicrobial peptide YD freeze-dried powder, and stored away from light.

[0113] The above-mentioned non-specific protein stabilizer and lyoprotectant are preferably mannitol, the excipient is preferably lactose, the osmotic pressure regulator is preferably NaCl, and the pH regulator is preferably citric acid / Tris-HCl buffer.

Embodiment 2

[0115] Preparation of Oral Preparation of Antimicrobial Peptide YD

[0116] Formula: antibacterial peptide YD (purity greater than 95%) 50.0g

[0117] Filler 85.0g

[0118] Adhesive 5.0g

[0119] Lubricant 10.0g

[0120] Total 200.0g

[0121] Process: 1,000 capsules are made according to the conventional process for preparing capsules, each capsule contains 50 mg of the active ingredient of antibacterial peptide YD, and the capsules are coated with an enteric-coated material acrylic resin to make an enteric-coated preparation. Excipients such as fillers, adhesives, and lubricants are conventional excipients in pharmacy.

[0122] In addition, oral preparations can also be made of microspheres, microcapsules, and nanospheres by wrapping the above-mentioned fillers, binders, lubricants and other auxiliary materials with polyester materials, and liposomes or nanospheres by wrapping chitosan. Granules, adding cholesterol, phospholipids and free fatty acids to prepare microemul...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biomedicine and relates to application of antibacterial peptide YD in preparing drug for treating hepatic fibrosis. The antibacterial peptide YD is antibacterialpeptide (APKGVQGPNG) separated and purified from bacillus amyloliquefaciens CBS antibacterial peptide YD1 reported in 2017, and in-vitro experiments prove that the antibacterial peptide YD has antibacterial activity and antioxidation activity. By allowing the antibacterial peptide YD to act on two cell models including a human hepatic satellite cell (LX-2) model and a lipopolysaccharide induced mice macrophage (RAW264.7) inflammation model and an in-vivo hepatic fibrosis mice model, it proves that the antibacterial peptide YD hinders occurrence and development of hepatic fibrosis by inhibitinginflammatory reaction, has effect of resisting hepatic fibrosis and is low in cytotoxicity, so that the antibacterial peptide YD can be taken as an active ingredient to prepare hepatic fibrosis resistant drug different in dosage forms by adopting pharmaceutically conventional processes and auxiliary materials, thereby having great medicinal application prospect.

Description

technical field [0001] The invention belongs to the technical field of biomedicine and relates to a new medical application of a polypeptide with antibacterial effect, in particular to the application of the antibacterial polypeptide antibacterial peptide YD in the preparation of drugs for treating liver fibrosis. Background technique [0002] Liver fibrosis is a complex physiological and pathological process involving various pathogenic factors, involving a variety of cells, cytokines, and signal transduction pathways. The pathological manifestation is mainly the synthesis of extracellular matrix (ECM) in the liver. The unbalance of degradation and degradation causes the deposition of extracellular matrix in the liver, causing structural changes in the liver and affecting liver function. If not treated in time, the process of fibrosis will develop into cirrhosis, liver failure and even liver cancer if it continues for a long time. Liver fibrosis is a common pathological pr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/08A61P1/16
CPCA61K38/08A61P1/16
Inventor 谢俊秋王锐闫志斌王丹
Owner LANZHOU UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com